Reducing recurrence of large colorectal polyps after removal
Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
This study is testing if a new method called hybrid argon plasma coagulation can help prevent large colorectal polyps from coming back after they've been removed, compared to the usual treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 892 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT06271941 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of hybrid argon plasma coagulation (h-APC) in reducing the recurrence of large colorectal polyps after endoscopic mucosal resection (EMR). Patients with large laterally spreading lesions (≥20mm) will be randomly assigned to receive either h-APC ablation or the standard snare tip soft coagulation (STSC) margin ablation. The trial aims to determine if the h-APC technique leads to lower rates of lesion recurrence compared to the current standard of care. Participants will undergo a standard colonoscopy preparation before the procedure, and the trial will be conducted at a single center in Montreal.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are undergoing EMR for large colorectal laterally spreading lesions.
Not a fit: Patients with inflammatory bowel disease, poor general health, or those with invasive cancer in the polyp will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the recurrence of colorectal polyps, thereby lowering the risk of colorectal cancer.
How similar studies have performed: While the specific approach of h-APC is novel, similar techniques have shown promise in reducing recurrence in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult ≥18 years old * patients undergoing EMR for a large (≥20mm) colorectal LSL * patients providing written and informed consent for study participation. Exclusion Criteria: * inflammatory bowel disease; * non-elective colonoscopy; * poor general health (American Society of Anesthesiologists classification \>III); * coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L); * pedunculated polyps (Paris class Ip, Isp); * overt signs of deep submucosal invasive cancer (JNET 3); * biopsy proven invasive carcinoma in a potential study polyp. * Pregnant women
Where this trial is running
Montreal, Quebec
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.